Headquartered in Indianapolis, IN Fiscal year ends December NYSE: CTVA corteva.com
Corteva, Inc. (NYSE: CTVA) is a global crop protection company, following the separation of its former Seed business into a separate company, Vylor. Its portfolio includes conventional chemistries such as herbicides (including acetochlor), insecticides and fungicides. It also offers biologicals, seed-applied technologies and nature-inspired products that help farmers increase yields and protect crops from weather stress, insects, weeds and diseases. Corteva sells through channel partners across North America (U.S. and Canada), EMEA, Latin America (with significant exposure to Brazil) and Asia Pacific. Growth is increasingly driven by new and differentiated products, while older molecules late in their lifecycle face competitive pricing pressure. The company is restructuring its Crop Protection manufacturing and external partner network, with the program expected to be substantially complete in 2028, and it maintains tax-indemnification arrangements with Dow, DuPont and Vylor. Updated
Brazil just broke Corteva's five-quarter streak of beating estimates, with Latin America organic sales down 31% on farmer liquidity problems and clogged channel inventory. Management trimmed full-year adjusted pro forma operating EBITDA guidance to $1.10 billion to $1.125 billion in the first quarter since the Vylor seed spin-off.
A 9.5% slide to $12.80 is a double-digit-scale day for a seed and crop protection name that rarely trades like this. At an $8.5 billion market cap, that is real value off the table in a single session.
Accenture opened 22% higher, a move you almost never see from a mega-cap IT services name, while Corteva dropped 82% to $13.96 at the other end of the board. Synopsys, McKesson and IBM round out a gainers list that is all up at least 5.9%.
One company just shed its seed business and must prove it can thrive on crop protection alone. The other has surged while its own metal sinks and analysts slash forecasts. November 11…
3M just turned its biggest open PFAS lawsuit into a payment schedule, but whether that deal actually holds depends on a participation threshold the company has not yet disclosed publicly.
Major corporate breakups are reshaping what shareholders own, but one company is doing it twice and another may hand you cash instead of a second stock. Knowing the difference before these deals…
Corteva shareholders woke up to what looked like an 83% crash, but the real story is what they now own across two tickers and a lawsuit that could unwind the entire split.
Omor Ibne Ehsan When investing for your retirement, you probably have a few objectives in mind. You won’t be working, for example, so you’ll want your investments to generate income that you can live on,…
Monday's top analyst upgrades and downgrades included Alibaba, Amazon.com, AppLovin, Corteva, Hershey, Lucid, Medical Properties Trust, Palo Alto Networks, Rivian Automotive, Twilio, Ventas, Walmart and Wayfair.
Tuesday's top analyst upgrades and downgrades included Apple, Azul, Conagra Brands, Corteva, CSX, Deere, DraftKings, Foot Locker, Intuit, KeyCorp, Nike, Salesforce, Take-Two Interactive Software, Union Pacific and Zions Bancorp.
Tuesday’s top analyst upgrades and downgrades included Alphabet, Amazon.com, Americold Realty Trust, Azek, Ball, Corteva, DraftKings, Dun & Bradstreet, Global Blood Therapeutics, Lululemon Athletica, Rhythm Pharmaceuticals and Western Digital.
J.P. Morgan recently issued a few calls across multiple industries that imply serious upside for each stock, but one in particular has up to more than 40% upside.
Here's a look at how markets were shaping up for Monday's opening bell.
Corteva, Inc. (NYSE: CTVA) is a global crop protection company, following the separation of its former Seed business into a separate company, Vylor. Its portfolio includes conventional chemistries such as herbicides (including acetochlor), insecticides and fungicides.
24/7 Wall St.'s 12-month price target for CTVA is $20.34, rated Buy. The Wall Street consensus target is $17.05. CTVA price prediction →
